产品
编 号：F300891
分子式：C20H20ClN5O2
分子量：397.86
分子式：C20H20ClN5O2
分子量：397.86
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 271576-80-8
产品详情
生物活性：
SD 0006 (SD-06) is an orally active, selective, ATP-competitive and potent diaryl pyrazole inhibitor of p38α MAP kinase, with an IC50 of 110 nM for p38α.
体内研究：
SD 0006 (0-30 mg/kg) may be an effective alternative to steroids and biologics for RA therapy.SD0006 (3.75, 7.5 and 15 mg/kg; p.o.; b.i.d.) is highly effective in attenuating SCW-induced inflammation as shown by the dose-dependent inhibition of paw swelling.Animal Model:8- to 12-week-old DBA/1 mice.
Dosage:3.75, 7.5 and 15 mg/kg.
Administration:Orally twice daily.
Result:Inhibited the transcription of several inflammatory mediators to prevent joint swelling and bone destruction and to preserve bone density.
体外研究：
SD 0006 clearly inhibits p38α as shown by the dose-dependent inhibition of phosphorylation of its endogenous Hsp27 substrate.
SD 0006 (SD-06) is an orally active, selective, ATP-competitive and potent diaryl pyrazole inhibitor of p38α MAP kinase, with an IC50 of 110 nM for p38α.
体内研究：
SD 0006 (0-30 mg/kg) may be an effective alternative to steroids and biologics for RA therapy.SD0006 (3.75, 7.5 and 15 mg/kg; p.o.; b.i.d.) is highly effective in attenuating SCW-induced inflammation as shown by the dose-dependent inhibition of paw swelling.Animal Model:8- to 12-week-old DBA/1 mice.
Dosage:3.75, 7.5 and 15 mg/kg.
Administration:Orally twice daily.
Result:Inhibited the transcription of several inflammatory mediators to prevent joint swelling and bone destruction and to preserve bone density.
体外研究：
SD 0006 clearly inhibits p38α as shown by the dose-dependent inhibition of phosphorylation of its endogenous Hsp27 substrate.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备